These two stocks could be rivals in the intense GLP-1 space in the future.Investing into companies involved with new weight loss medications can be overwhelming. There is a lot of competition in the space given the potential for the anti-obesity market to grow to a size of $100 billion or more, as per estimates from Goldman Sachs.The challenge becomes the following: Do you invest in an established healthcare company that is expanding into this new category of glucagon-like peptide-1 (GLP-1) medications, or ...

Company Performance - Amgen's stock closed at $332.80, reflecting a -0.73% change from the previous day's closing price, underperforming the S&P 500 which gained 0.03% [1] - Over the past month, Amgen's shares increased by 2.22%, while the Medical sector rose by 2.67% and the S&P 500 by 1.54% [1] - The upcoming earnings report is anticipated to show an EPS of $5.13, a 3.43% increase year-over-year, and revenue of $8.51 billion, indicating a 23.24% increase compared to the same quarter last year [1] Annual Estimates - For the annual period, earnings are projected at $19.49 per share and revenue at $33.21 billion, representing increases of +4.5% and +17.82% respectively from the previous year [2] Analyst Estimates and Valuation - Recent changes in analyst estimates for Amgen indicate a dynamic business outlook, with positive revisions suggesting optimism [2] - Amgen currently holds a Zacks Rank of 3 (Hold), with a consensus EPS projection that has decreased by 0.06% in the last 30 days [3] - The company is trading at a Forward P/E ratio of 17.2, which is lower than the industry average of 23.02, and has a PEG ratio of 2.98 compared to the industry average of 2.28 [3] Industry Context - The Medical - Biomedical and Genetics industry, to which Amgen belongs, has a Zacks Industry Rank of 79, placing it in the top 32% of over 250 industries [3] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [4]

Results Illustrate Depth and Diversity of Amgen's Targeted Therapies Across Tumor TypesTHOUSAND OAKS, Calif., Sept. 13, 2024 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the presentation of new data across its broad oncology pipeline and portfolio at the European Society for Medical Oncology (ESMO) Congress 2024, taking place Sept. 13-17 in Barcelona. The abstracts showcase data from Amgen-sponsored and investigator-sponsored studies for colorectal, lung, prostate and gastric cancers using molecular ...

Amgen is a decently valued stock that has an excellent business and also gives investors a way to potentially gain exposure to a lucrative weight loss market.If you want to invest in the fast-growing weight loss industry, going with stocks such as Eli Lilly or Novo Nordisk can seem like a great idea. They have leading weight loss products and possess some promising long-term growth opportunities. But they are already among the most valuable healthcare stocks in the world (their valuations are in excess of $ ...

Hispanolistic/E+ via Getty Images Investment Overview — Tango's Share Price Volatility Based On Competitor's Progress When I last covered Tango Therapeutics, Inc. (NASDAQ:TNGX) for Seeking Alpha, in January of this year, I gave the stock a “Buy” rating. I highlighted the fact that the Boston, Massachusetts-based biotech is one of only five companies to date — the others are Bristol Myers Squibb (BMY) (via its ~$5.8bn acquisition of Mirati Therapeutics), Amgen (AMGN), AstraZeneca (AZN), Johnson & Johnson ...

Central Press/Hulton Archive via Getty Images Written by Sam Kovacs Introduction Buy Low, Sell High, Get Paid To Wait. This is our investment philosophy. I make a point of repeating it as often as I can because it is so simple and elegant, that most investors overlook it. Einstein famously said that everything should be made as simple as possible, but not simpler. Well, this is as simple as it gets for investing. Of course, it brings up quite a few questions: what's low? What's high? Why get paid to wai ...

Summary of Amgen Inc. Conference Call Company Overview - **Company**: Amgen Inc. (NASDAQ: AMGN) - **Event**: Wells Fargo 2024 Healthcare Conference Call - **Date**: September 5, 2024 Key Points Industry and Company Mission - Amgen's mission is to serve patients by discovering, developing, manufacturing, and delivering innovative medicines for serious illnesses globally [6][7] Financial Performance - In Q2 2024, Amgen reported revenues of $8.4 billion, a 20% increase year-over-year, marking the highest quarterly revenues in the company's history [9] - Twelve products achieved double-digit sales growth in the same quarter [9] Product Pipeline and Growth Areas - Amgen has a strong long-term growth outlook across four therapeutic areas: general medicine, oncology, hematology, and rare diseases [7][22] - Key brands driving growth include Repatha, EVENITY, BLINCYTO, and TEZSPIRE, with Repatha and EVENITY growing 25% and 39% respectively in Q2 [10][12] - Significant milestones achieved in 2024 include: - Accelerated approval of IMDELLTRA for small cell lung cancer - Approval of BLINCYTO for frontline treatment of B-cell precursor acute lymphoblastic leukemia - Positive Phase III data for UPLIZNA in IgG4-related disease [8][9] Research and Development Focus - Amgen is prioritizing internal innovation, with a capital allocation strategy focused on R&D [20][21] - The company is excited about the upcoming Phase II data for MariTide, an antibody peptide conjugate targeting obesity and related conditions, expected by the end of 2024 [26][28] - Olpasiran, a small interfering RNA targeting Lp(a), is undergoing a Phase III trial to assess its impact on cardiovascular risk [35][36] Manufacturing and Capacity Expansion - Amgen is investing in manufacturing capabilities, with significant expansions in Ohio and North Carolina to support future product launches [55][58][59] - The company raised its capital expenditure guidance from $1.1 billion to $1.3 billion for the year, indicating a commitment to enhancing manufacturing capacity [59] Competitive Landscape and Market Position - UPLIZNA is positioned as a competitive treatment for myasthenia gravis, with a focus on eradicating CD19 positive B cells, which may offer advantages over existing therapies [49][50] - The company is leveraging its experience from the Repatha launch to maximize the potential of new products in the cardiovascular space [41][42] Future Outlook - Amgen is optimistic about its innovative pipeline and the potential impact of its therapies on patient care, emphasizing a patient-centric approach [24][60] - The company is committed to maintaining a strong focus on innovation and operational excellence to drive future growth [18][19] Additional Insights - The leadership team highlighted the importance of a collaborative and innovative culture within the company, which is crucial for advancing its research and development efforts [19] - The strategic focus on high-impact medicines and rigorous prioritization of projects is expected to enhance the company's growth trajectory [16][20]

A month has gone by since the last earnings report for Amgen (AMGN) . Shares have added about 5.8% in that time frame, underperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Amgen due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. Q2 Earnings & Sales BeatAmgen’s second-quarter results were s ...

Amgen (AMGN) stock has risen 19.6% in the past six months compared with an increase of 12.4% for the industry. The stock has also outperformed the sector and the S&P 500 index, as seen in the chart below.AMGN Stock Outperforms Industry, Sector & S&P 500Image Source: Zacks Investment ResearchThe stock has also been consistently trading above its 50-day and 200-day moving averages since early August.One of the key reasons for the recent stock price outperformance has been its strong second-quarter results, as ...

Company and Industry Overview * **Company**: Amgen Inc. (NASDAQ: AMGN) * **Industry**: Biopharmaceuticals * **Focus**: Developing innovative medicines for unmet medical needs in general medicine, oncology, inflammation, and rare diseases. Key Points Business Performance * **General Medicine**: Repatha and EVENITY continue to grow strongly, with Repatha up 25% in Q2 2024 and EVENITY up 40%. * **Oncology**: Oncology portfolio up 12% on the quarter, driven by strong performance across multiple medicines. * **Inflammation**: TEZSPIRE grew 75% in Q2 2024, with potential to be a game-changing medicine. * **Rare Diseases**: TEPEZZA, KRYSTEXXA, and UPLIZNA are performing well, with UPLIZNA showing spectacular data in IgG4-related disease. * **Pipeline**: Strong pipeline with visible molecules in each area, including bispecifics, novel biologics, and next-generation assets. Strategy and Growth * **Innovation**: Focus on innovation and addressing unmet medical needs. * **International Growth**: Well-established globally, with strong growth in Asia and other international markets. * **Pipeline**: Exciting pipeline with multiple late-stage programs and next-generation assets. * **Biosimilars**: Developing biosimilars to augment existing products and expand market access. Policy and Regulatory * **Inflation Reduction Act (IRA)**: Concerns about the impact of IRA on innovation and investment in the industry. * **Policy Engagement**: Active engagement in Washington D.C. to ensure understanding of the biopharmaceutical industry and the impact of policies like IRA. Pipeline Details * **MariTide**: Next-generation obesity asset with a different mechanism of action and dosing advantage compared to existing treatments. * **Rocatinlimab**: Novel OX40 antibody for atopic dermatitis, prurigo nodularis, and respiratory diseases. * **Olpasiran**: Novel Lp(a) lowering therapy for patients at high risk of cardiovascular disease. * **AI**: Investing in AI to accelerate drug discovery and development. Other Important Points * **Horizon Integration**: Integration of Horizon Therapeutics is progressing well, with a strong fit between teams and exciting potential for future growth. * **Puerto Rico Tax Litigation**: High confidence in a favorable outcome in the tax court later in the year.